Taking responsibility: Asilomar and its legacy
By J. Benjamin Hurlbut,
Science
| 01. 30. 2025
In February 1975, leading molecular biologists gathered at the Asilomar conference center on the California coast to evaluate risks of the emerging technology of recombinant DNA and to establish guidelines to govern research. The meeting is remembered as a defining moment in the making of molecular biology. Yet its legacy lies not in specific rules it developed but in the approach to scientific self-regulation that it crystallized. Five decades later, this near-mythic “meeting that changed the world” is held up as a precedent to celebrate and a model to emulate: Scientists take responsibility for governing themselves, solidifying public trust while securing future benefits of technology for society. But although this may elicit public acquiescence and secure scientific autonomy in the short run, ultimately it has engendered reactive distrust. The 50th anniversary affords a moment for taking stock of Asilomar’s legacy and its implications for science and democracy. Its lessons are difficult.
The Asilomar meeting is held up as an exemplar of how scientists can navigate between the Scylla of technological risk and the Charybdis of public reaction and overregulation (...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...